Metraipolis › archive › dc_06ce27dbf99d

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42350643
DOI
10.1038/s41591-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-10-31T08:50:58.467Z
SHA-256 of the archived text
85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5
Stable URL of this page
https://metraipolis.com/documento/dc_06ce27dbf99d

How to cite

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643 — Europe PMC (en), https://europepmc.org/article/MED/42350643 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_06ce27dbf99d (Metraipolis archive dc_06ce27dbf99d, sha256 85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5)
BibTeX
@misc{dc06ce27dbf99d,
  title = {Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42350643},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_06ce27dbf99d; sha256 85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42350643. Agents can read the archived copy with the MCP tool read_document.